Ingavirin^®

An innovative drug for the treatment and prevention of influenza (types A and B) and other acute respiratory infections (rhinovirus, MS virus, adenovirus, etc.).

A unique mechanism of action (it is not an interferon inducer).

It has a wide spectrum of action and is approved for use in influenza and acute respiratory viral infections in adults and children from 6 months^*.

Convenient admission scheme (1 time per day, 1 week of admission, 1 package per course).

High safety profile and level of evidence (12 clinical trials of Ingavirin^® were conducted, meeting international standards of evidence-based medicine with the participation of more than 2,300 people).

Included in modern standards for the treatment of influenza and SARS, including Temporary Guidelines for the prevention, diagnosis and treatment of new coronavirus infection (COVID-19).

Ingavirin^® promotes^1-3: 

• reduction of viral load;
• accelerated virus elimination;
• reducing the risk of developing the disease after contact with a person infected with influenza and SARS;
• reducing the duration of the disease;
• reducing the risk of complications.

Indications for use:

Treatment of influenza A and B and other acute respiratory viral infections (adenovirus infection, parainfluenza, respiratory syncytial infection, rhinovirus infection) in adults and children from 6 months^*.

Prevention of influenza A and B and other acute respiratory viral infections (adenovirus infection, parainfluenza, respiratory syncytial infection, rhinovirus infection) in adults and children from 3 years.

^*Please note that before using Ingavirin^® syrup with a volume of 50 ml in patients from 6 months to 2 years (inclusive), it is necessary to consult a specialist.

¹Instructions for use of the medicinal product for medical use Ingavirin^®, LSR-006330/08

² Instructions for use of the medicinal product for medical use Ingavirin^®, LP-002968

³Instructions for use of the medicinal product for medical use Ingavirin^®, LP-006482